bpc 157 venous insufficiency Pentadecapeptide as Therapy for Inferior Caval Vein Embolization: Recovery of Sodium Laurate-Post-Embolization Syndrome in Rats The Hidden Risks of BPC‑157:

Systemic adverse effects appear to be uncommon based on available reports, but comprehensive adverse event profiles are lacking due to the paucity of large-scale clinical investigations

One should consider the primary phase lesion and hemorrhaging that results from mechanical damage during SCI as well as the secondary phase lesion that lasts several hours or even several months and is accompanied by edema, hemorrhage, inflammation, and cytotoxic edema [4447] and may extend to the white matter area and lead to white matter degeneration and damage [48, 49]

Ongoing research efforts are shedding light on the potential of BPC-157 in revolutionizing tendonitis recovery

Because amylin and GLP 1 signaling influence several metabolic systems at once, researchers expect CagriSema to have broader benefits than weight alone once larger trials are completed

It is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed to these adverse events